Effects of radioiodine on thyrotrophin binding inhibiting immunoglobulins in Graves' disease.
We have studied the effects of 131I therapy on thyrotrophin binding inhibiting immunoglobulins (TBII) in fifty-five patients with Graves' disease and five patients with toxic multinodular goitre (MNG). A group of forty patients with Graves' disease and four patients with toxic MNG were treated with drugs and acted as controls. In 78% of patients treated with 131I there was a marked increase in the serum TBII activity during the 3 months following therapy, whereas drug-treated patient showed a decrease (77%) or no change in TBII activity over the same period. TBII activity was not detectable in patients with toxic MNG before or after drug or 131I therapy. Consideration of the mechanisms involved in the changes in serum TBII activity after 131I treatment or during drug treatment provide insight into the basic defects responsible for the development of hyperthyroid Graves' disease and suggest that both the thyroid and immune system are involved.
D005260:Female; D006044:Goiter, Nodular / Q000097:blood; D006111:Graves Disease / Q000097:blood* / Q000532:radiotherapy; D006801:Humans; D007136:Immunoglobulins / Q000276:immunology; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011485:Protein Binding; D013961:Thyroid Gland / Q000276:immunology; D013972:Thyrotropin / Q000378:metabolism*
D007136:Immunoglobulins; D007457:Iodine Radioisotopes; D013972:Thyrotropin